Metabolomic Profiling Has the Potential to Differentiate Between Iron Deficiency Anemia and Anemia of Inflammation
Triin Paabo, Eliis Grigor, Egon Taalberg, Natalja Luppova et autres
0 citationsMetabolites
Ain Kaare
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
28Publications signalées
127Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Acute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationAcute Lymphoblastic Leukemia researchMultiple Myeloma Research and TreatmentsChronic Myeloid Leukemia Treatments
Publications récentes
Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed By Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind phase 3 Study (HOVON 181 AML / AMLSG 37-25)
Marc Raaijmakers, Hartmut Döhner, Dimitri A Breems, John C. Byrd et autres
0 citationsTransplantation and Cellular Therapy
CAR-T-ravi refraktaarse või retsidiveerunud difuusse B-suurrakklümfoomi ravis: tervisetehnoloogia hindamise raport TTH80
Katrin Koiduaru, Martin Müürsepp, Ain Kaare, Janika Alloja et autres
0 citationsDSpace repository (University of Tartu)
Extracorporeal photopheresis: health technology assessment report HTA82
Martin Müürsepp, Janika Alloja, Katrin Koiduaru, Ain Kaare et autres
0 citationsDSpace repository (University of Tartu)
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP
Ali Bazarbachi, Jacques‐Emmanuel Galimard, Iman Abou Dalle, Myriam Labopin et autres
1 citationBone Marrow Transplantation
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
Marc H.G.P. Raaijmakers, Hartmut Döhner, Dimitri Breems, John C. Byrd et autres
2 citationsBlood
Impact of Wilms’ tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry
Arnon Nagler, Jordi Esteve, Jacques‐Emmanuel Galimard, Jaime Sanz et autres
1 citationBone Marrow Transplantation
Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group
Kari Lenita Falck Moore, Sæmundur Rögnvaldsson, Agoston Gyula Szabo, Vilmantė Vaitekėnaitė et autres
0 citationsHaematologica
Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWP
Ali Bazarbachi, Jacques‐Emmanuel Galimard, Iman Abou Dalle, Myriam Labopin et autres
0 citationsResearch Square
Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report
Pedro Henrique Prata, Dirk-Jan Eikema, Brian Piepenbroek, Austin Kulasekararaj et autres
1 citationHaematologica
Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Ali Bazarbachi, Jacques‐Emmanuel Galimard, Myriam Labopin, Iman Abou Dalle et autres
0 citationsBlood
Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
Arnon Nagler, Jordi Esteve, Jacques‐Emmanuel Galimard, Jaime Sanz et autres
0 citationsBlood
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.